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PRECIS  
 Agreement among uveitis experts on the diagnosis of 5766 cases for 25 
diseases was moderate (overall mean κ=0.39), suggesting that groups of patients 
reported in the literature may not always be comparable.  After formalized consensus 
conference calls, agreement was reached on 99% of cases, implying that validated and 
widely-used classification criteria for the uveitides may improve this situation.    
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 The uveitides are a collection of over 30 diseases characterized by intraocular 
inflammation.1-3  They can be thought of as a matrix of diseases classified by the 
primary site of inflammation (anatomic class) and by whether they are infectious in 
nature, associated with a systemic auto-inflammatory or auto-immune disease, or eye-
limited and presumed to be immune mediated.1  The diagnosis of the specific uveitic 
disease is made by a combination of the clinical features and selected laboratory 
testing.1,2   
 
 Classification criteria are a method of diagnosing individual diseases for research 
purposes.4 They differ from clinical diagnostic criteria, in that although they seek to 
maximize sensitivity and specificity (e.g. minimize misclassification), when a trade-off is 
needed, they emphasize specificity over sensitivity.4  The goal of classification criteria is 
to define a homogeneous group of patients for inclusion in clinical research projects, 
such as clinical trials, prospective cohort studies, and translational or pathogenesis 
research. Hence the criteria seek to optimize the likelihood that all patients in the project 
are generally accepted to have the disease.  Among the best recognized classification 
criteria are those developed for the rheumatic diseases, such as rheumatoid arthritis, 
systemic lupus erythematosus, spondyloarthritides, and juvenile idiopathic arthritis 
subgroups.5-12  These criteria have used datasets of cases submitted for the project(s) 
to develop and evaluate the criteria.  Furthermore, they have been revised over time as 
new information has become available.5-12   
 
 In the field of uveitis, diagnostic criteria have been proposed for several 
diseases, but there has been limited formal evaluation of many of these criteria.13-22  
The Standardization of Uveitis Nomenclature (SUN) Working Group is an international 
collaboration dedicated to improving clinical research in the field of uveitis.2  They are 
developing classification criteria for the leading 25 uveitides using a formal approach to 
development and evaluation.3,23   
 
 The “SUN Developing Classification Criteria for the Uveitides” project is 
proceeding in 4 phases:  1) informatics, 2) case collection, 3) case selection, and 4) 
machine learning.3,23  The informatics phase developed a standardized vocabulary and 
set of dimensions for describing cases of uveitis.  It enabled the development of a 
standardized, “drop-down-menu” driven, hierarchical case report form for collecting 
information on uveitides.3,23  Case collection was accomplished by individual 
investigators from each of the 65 clinical centers entering data into a preliminary data 
base using the standardized form.  Case selection involved committees of nine 
individuals reviewing each case to determine whether they agreed with the diagnosis, 
thereby developing a final database of cases with supermajority agreement on the 
diagnosis from the preliminary database.  The machine learning phase will evaluate the 
features of each disease and compare them to other diseases in the differential 
diagnosis in order to develop a parsimonious set of criteria for each of the 25 diseases 
under consideration that minimizes misclassification for each disease.   
 
 The case selection phase of the project included an independent online voting 
step by each committee member, in which they decided to “accept” the case if they 
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agreed with the diagnosis or “reject” it, if they did not.  This online voting step permitted 
the evaluation of the agreement among uveitis experts on the diagnosis of these 
diseases.   
 
Methods 
 Case collection.  Information was entered into the SUN database by the 76 
contributing investigators for each of the 25 diseases under consideration.  The data 
were entered into a “drop-down-menu” driven form using the terminology developed 
during the informatics phase of the study to maximize discreet data collection and 
minimize free text.  For selected relevant diseases (e.g. posterior and pan-uveitides), 
the investigators also uploaded imaging (e.g. fundus photographs, fluorescein 
angiograms, optical coherence tomography) sufficient to assist with the diagnosis.  
Case information was de-identified, and investigators entered cases retrospectively 
from existing case records.  Investigators were instructed to enter the data from the 
presentation visit, or in the unusual case where there was disease evolution, the visit at 
which the diagnosis first was known.  The target was 250 cases for each disease, and 
once that number was reached, case entry for that disease was closed.  For several 
diseases, typically less common ones, a final number less than 250 was achieved.  For 
a few diseases, the number of cases entered exceeded as cases were entered from 
multiple centers, and extra cases were entered just prior to closing the disease.  In 
order to have a sufficient number of cases of the several manifestations of sarcoidosis, 
additional cases were entered and the upper limit was set at approximately 400.   
 Case selection.  The case selection phase of the project was designed to ensure 
that cases in the final database were widely accepted (i.e. accepted by a supermajority 
of clinicians) as having the disease.  Committees of nine individuals, geographically and 
“school of thought” dispersed, were constituted to review the cases for each disease.  
Five committees worked in parallel:  anterior uveitides; intermediate and pan-uveitides; 
posterior uveitides; infectious posterior and pan-uveitides; and other diseases (e.g. 
tubulointerstitial nephritis with uveitis and sarcoidosis).  Case selection occurred in two 
steps:  online voting and consensus conference calls.  During the online voting step, 
each committee member reviewed the each case’s information independently and then 
voted to include the case in the final database (“accept”) or exclude it (“reject”).  The 
information was presented on standardized forms, using standardized terminology and 
descriptive phrases derived during the informatics phase23 (see supplemental figure, 
available online at ajo.com).  A “forced choice” was required, and committee members 
were instructed to vote on whether they thought the diagnosis was correct using their 
clinical judgment.  Any case getting a supermajority of online votes to accept (>75%) 
was included in the final database, and any case getting a supermajority of online votes 
to reject was excluded.  Cases with less than a supermajority were tabled for consensus 
conference calls.  Diseases were addressed sequentially by each committee.     
 Consensus conference calls were conducted for all tabled cases for each 
disease on a disease by disease basis using nominal group techniques.24  Nominal 
group techniques are a formalized discussion approach for achieving consensus, 
designed to ensure participation from each member and avoid “dominant personality” 
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effects.  In short, for each case tabled in the online voting step, each committee 
member makes a brief, uninterrupted comment about the case; after all committee 
members had commented, there was anonymous “real time” online voting.  Cases 
getting a supermajority (>75%) of “accept” votes were accepted into the final database 
without further discussion, and cases getting a supermajority of “reject” votes were 
excluded.   Cases neither accepted nor rejected were subjected to a second round of 
comments and voting.  Cases neither accepted nor rejected after the second round of 
voting were permanently tabled and were not included in the final database.24   
 The study adhered to the principles of the Declaration of Helsinki.  Institutional 
review boards (IRBs) at each participating institution reviewed and approved the study; 
the study typically was considered either minimal risk or exempt by the individual IRBs.   
 The independent online voting step provided the opportunity to evaluate the 
agreement on diagnosis among uveitis experts.  For each disease, pairwise kappas (κ) 
were calculated between each pair of committee members.  Hence for each disease, 
there were 36 pairwise κ’s; for each disease, a mean, standard deviation, and range of 
the κ’s were calculated.  The κ statistic is an agreement statistic that corrects for 
agreement by chance alone.  It ranges from -1.00 (zero agreement) to 1.00 (perfect 
agreement), with κ=0 representing chance agreement.   Kappas above 0.70 are 
considered “substantial”, and above 0.85 “almost perfect”.25,26     
Results 
 
 A total of 5766 cases were collected for the 25 diseases under consideration.  
Because of the important differential diagnosis between serpiginous choroiditis and 
serpiginous-like tuberculous choroiditis, the latter were collected specifically in addition 
to other cases of tuberculous choroiditis.  Also because of the very different 
manifestations of early and late Vogt-Koyanagi-Harada disease, separate datasets were 
collected for each.   
 
 The mean κ from the online voting for the entire project was 0.39 (moderate 
agreement) with a range of disease-specific mean κ’s from 0.23 for toxoplasmic retinitis 
to 0.79 for cytomegalovirus (CMV) anterior uveitis (table 1).  For the entire project, only 
one pair of individuals had perfect agreement (κ=1.00), and this occurred in CMV 
anterior uveitis.   For several diseases, there was at least one pair of individuals whose 
agreement was essentially “chance alone” (κ ~ 0.00); diseases where there were two 
individuals who agreed at or close to “chance alone” (κ <0.10) included herpes simplex 
anterior uveitis,  juvenile idiopathic arthritis associated uveitis, pars planitis, multifocal 
choroiditis with panuveitis, serpiginous choroiditis, serpiginous-like tuberculous 
choroiditis, CMV retinitis, toxoplasmic retinitis, tuberculous uveitis, and sympathetic 
ophthalmia.   
 
 For the entire project, after the consensus conference calls, 71% of the submitted 
cases were accepted into the final database, and 28% were rejected.  Approximately 
1% of submitted cases were permanently tabled.  Disease-specific acceptances into the 
final data base ranged from 42% (for herpes simplex anterior uveitis) to 92% for 
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serpiginous-like tuberculous choroiditis.  Disease-specific permanent tabling of 
submitted cases ranged from 0% for several diseases to 4% for spondylitis/HLA-B27-
associated uveitis with the majority of diseases in the 0-1% range.   
 
Discussion 
 
 Our data suggest that, when functioning independently, agreement among uveitis 
experts on the diagnosis of the specific disease entity is moderate at best, although 
there is variation by specific uveitic disease.  Diseases in which there was good 
agreement were those for which there is a specific laboratory test, such as CMV 
anterior uveitis.  The diagnosis of CMV anterior uveitis rarely is made without detection 
of CMV DNA in the anterior chamber on polymerase chain reaction (PCR) testing of 
anterior chamber paracentesis fluid.   
 
 Diseases which had lower κ’s were those that are morphologically diagnosed, 
such as multifocal choroiditis with panuveitis and infectious retinitides.  Similar problems 
arose when there was a laboratory test that is a risk factor (e.g. HLA-B27) but does not 
automatically diagnose the disease due to the population frequency of a positive test 
result and the resultant need to determine if the clinical picture is compatible with the 
disease, and those diseases where a test was necessary but not sufficient to make the 
diagnosis (e.g. testing for tuberculosis), due to the frequency of an unrelated abnormal 
test result in the population being studied.  Disagreements also were encountered 
where there were two possible diagnoses.  Herpes simplex virus (HSV) anterior uveitis 
and varicella zoster virus (VZV) anterior uveitis are illustrative.  Although PCR for 
viruses can be performed to establish the diagnosis, the disease often is diagnosed 
morphologically.  Some related clinical features can be used reliably (e.g. presence of 
documented HSV keratitis or dermatomal zoster) to aid in diagnosis without laboratory 
confirmation.  Studies employing anterior chamber paracentesis and PCR of patients 
with anterior uveitis and sectoral iris atrophy have shown that in over 95% of cases 
these patients have either HSV or VZV.27 Patients with HSV are younger at onset (less 
than 60 years of age with a mean of 34 years), and those with VZV are older (over 50 
years of age with a mean of 65 years).  Hence it can be reasonably inferred that a 
patient under 50 years of age with anterior uveitis with sectoral iris atrophy has HSV 
anterior uveitis, whereas a patient over 60 years of age with anterior uveitis and sectoral 
iris atrophy has VZV anterior uveitis.  However, in the absence of PCR testing or other 
cardinal features, it may not be possible to be certain of the diagnosis in patients 
between 50 and 60 years of age.   
 
 These data also suggest that in the absence of validated and widely-used 
classification criteria, case series from different centers may not be reporting the 
comparable sets of patients. This is of particular concern where the range of pairwise 
κ’s included a pair with agreement close to “chance alone” agreement.   
 
 However, the ability to reach supermajority agreement on the diagnosis for 99% 
of cases after the consensus conference calls suggests that uveitis experts are capable 
of agreement after discussion of the case.  Furthermore, it implies that validated and 
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widely used classification criteria for the uveitides should result in case series, cohorts, 
and clinical trials from different centers which should be more comparable, as they will 
contain a more homogeneous group of patients.  It was the experience of the individuals 
involved in the consensus conference calls that during the calls a sense of the essential 
features for making the diagnosis and excluding the diagnosis began to emerge.   
 
 Although the approach was rigorous, and in general the number of cases of each 
disease reasonably large, there are caveats to the data.  For some diseases the 
number of cases was not in the 200-250 range.  The requirement for supermajority 
agreement for a case to be included in the final database was fundamentally 
conservative and may exclude cases considered by many investigators to have the 
disease.  However, this requirement is necessary for classification criteria (as opposed 
to diagnostic criteria) as the goal is high specificity and a homogeneous group of 
patients generally accepted to have the disease.4  Furthermore, this requirement does 
not influence the κ‘s derived from the independent online voting, only the results about 
inclusion in the final database.  Group dynamics are susceptible to “dominant 
personality” effects, and there can be a falsely elevated level of agreement if the group 
is not representative of the population at large.  These effects were addressed by using 
nominal group techniques, which minimize “dominant personality” effects, and by the 
international composition of the groups with efforts to make them geographically and 
“school of thought” dispersed.24 Moreover, these potential effects would affect the 
agreement from the consensus conference calls but not the independent online voting 
being evaluated by the κ‘s reported herein.   
 
 The accepted “final” data set will be used in machine learning approaches to 
arrive at a parsimonious set of criteria for each disease that minimizes misclassification.  
The data set will be split into two groups, a learning set and a test set, to develop and 
test the diagnostic algorithms developed, respectively.  Critically, the developed criteria 
should optimize classification within uveitic class.  A variety of statistical techniques may 
be employed, including logistic regression and classification and regression trees.28,29   
 
 In conclusion, our results suggest that currently, in the absence of validated and 
widely-used classification criteria, the agreement among uveitis experts on diagnosis is 
moderate with disease-specific variation.  The results of the consensus conference 
calls, after which 1% of cases were permanently tabled, suggest that uveitis experts can 
agree on the diagnosis after discussion and suggest that validated and widely-used 
classification criteria may improve this situation.    
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Table 1.  Inter-observer Agreement among Uveitis Experts on Uveitic Diagnosis 
 
 
Disease  
Number 
cases 
submitted 
 
Online Voting Results 
Final Results after Consensus 
Conference (% cases) 
Mean κ SD* Range κ’s† Accepted Rejected Tabled 
Cytomegalovirus anterior uveitis 112 0.79 0.15 0.51, 1.00 82 17 1 
Herpes simplex anterior uveitis 250 0.32 0.14 0.00, 0.56 42 56 2 
Varicella zoster anterior uveitis 163 0.58 0.10 0.35, 0.87 76 23 1 
Fuchs uveitis syndrome 249 0.44 0.13 0.16, 0.65 59 41 <1 
Juvenile idiopathic arthritis chronic uveitis 251 0.29 0.16 -0.02, 0.64 80 19 1 
Spondylitis/HLA-B27 associated uveitis 251 0.47 0.11 0.27, 0.71 74 22 4 
Tubulointerstitial nephritis with uveitis 125 0.54 0.22 0.16, 0.87 76 24 0 
Pars planitis 308 0.32 0.15 -0.04, 0.63 74 25 1 
Intermediate uveitis, non-pars planitis type 209 0.49 0.09 0.27, 0.67 55 45 0 
Multiple sclerosis associated uveitis 183 0.44 0.08 0.31, 0.62 62 38 <1 
Acute Posterior Multifocal Placoid Pigment 
Epitheliopathy 
149 0.44 0.12 0.17, 0.84 52 48 0 
Birdshot chorioretinitis 257 0.36 0.09 0.20, 0.57 81 18 1 
Multiple evanescent white dot syndrome 95 0.39 0.12 0.10, 0.75 54 44 2 
Multifocal choroiditis with panuveitis 251 0.30 0.13 0.02, 0.58 57 42 1 
Punctate inner choroiditis 250 0.52 0.08 0.32, 0.70 58 42 0 
Serpiginous choroiditis 157 0.37 0.19 -0.02, 0.69 78 22 <1 
Serpiginous-like tuberculous choroiditis 104 0.28 0.15 -0.02, 0.55 92 8 0 
Acute retinal necrosis 252 0.43 0.18 0.13, 0.61 75 25 <1 
Cytomegalovirus retinitis 251 0.27 0.16 0.07, 0.65 84 16 0 
Syphilitic uveitis 250 0.47 0.12 0.15, 0.68 86 14 0 
Toxoplasmic retinitis 213 0.23 0.14 0.03, 0.53 82 17 1 
Tuberculous uveitis 254 0.24 0.16 0.01, 0.58 71 27 2 
Behçet disease 248 0.36 0.13 0.15, 0.61 80 18 2 
Sarcoid uveitis 383 0.56 0.15 0.23, 0.86 72 28 0 
Sympathetic ophthalmia 149 0.31 0.12 0.07, 0.51 75 25 <1 
Vogt-Koyanagi-Harada disease, early 224 0.45 0.14 0.16, 0.72 69 30 1 
Vogt-Koyanagi-Harada disease, late 177 0.42 0.14 0.13, 0.68 58 41 1 
Overall 5766 0.39 0.14 -0.04, 1.00 71 28 1 
*SD = standard deviation.  †Range of the κ’s for the pairwise comparisons within a disease.   
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FIGURE LEGEND.   
 
Supplemental figure.  Form for online case selection.  Clinical and laboratory data were 
populated with information collected during case collection using drop-down menus of  
standardized terms and phrases derived from the informatics phase (see reference 23).  
